171 related articles for article (PubMed ID: 34662181)
1. Efficacy of an Acid-Oxidizing Solution against Mycobacterium ulcerans.
Warryn L; Pluschke G
Antimicrob Agents Chemother; 2022 Jan; 66(1):e0087021. PubMed ID: 34662181
[TBL] [Abstract][Full Text] [Related]
2. Buruli Ulcer: Review of a Neglected Skin Mycobacterial Disease.
Guarner J
J Clin Microbiol; 2018 Apr; 56(4):. PubMed ID: 29343539
[TBL] [Abstract][Full Text] [Related]
3. Shortening Buruli Ulcer Treatment with Combination Therapy Targeting the Respiratory Chain and Exploiting Mycobacterium ulcerans Gene Decay.
Converse PJ; Almeida DV; Tyagi S; Xu J; Nuermberger EL
Antimicrob Agents Chemother; 2019 Jul; 63(7):. PubMed ID: 31036687
[TBL] [Abstract][Full Text] [Related]
4. [Paradoxical reactions and responses during antibiotic treatment for Mycobacterium ulcerans infection (Buruli ulcer). Four cases from French Guiana].
Sambourg E; Dufour J; Edouard S; Morris A; Mosnier E; Reynaud Y; Sainte-Marie D; Nacher M; Guégan JF; Couppié P
Ann Dermatol Venereol; 2014; 141(6-7):413-8. PubMed ID: 24951139
[TBL] [Abstract][Full Text] [Related]
5.
Chamseddine S; Hindy JR; Haddad SF; Kanj SS
BMJ Case Rep; 2022 Aug; 15(8):. PubMed ID: 35944937
[No Abstract] [Full Text] [Related]
6. Buruli Ulcer, a Prototype for Ecosystem-Related Infection, Caused by Mycobacterium ulcerans.
Zingue D; Bouam A; Tian RBD; Drancourt M
Clin Microbiol Rev; 2018 Jan; 31(1):. PubMed ID: 29237707
[TBL] [Abstract][Full Text] [Related]
7. Clinical and bacteriological efficacy of rifampin-streptomycin combination for two weeks followed by rifampin and clarithromycin for six weeks for treatment of Mycobacterium ulcerans disease.
Phillips RO; Sarfo FS; Abass MK; Abotsi J; Wilson T; Forson M; Amoako YA; Thompson W; Asiedu K; Wansbrough-Jones M
Antimicrob Agents Chemother; 2014; 58(2):1161-6. PubMed ID: 24323473
[TBL] [Abstract][Full Text] [Related]
8. High-Dose Rifamycins Enable Shorter Oral Treatment in a Murine Model of Mycobacterium ulcerans Disease.
Omansen TF; Almeida D; Converse PJ; Li SY; Lee J; Stienstra Y; van der Werf T; Grosset JH; Nuermberger EL
Antimicrob Agents Chemother; 2019 Feb; 63(2):. PubMed ID: 30455239
[TBL] [Abstract][Full Text] [Related]
9. Providing insight into the incubation period of Mycobacterium ulcerans disease: two case reports.
Amoako YA; Frimpong M; Awuah DO; Plange-Rhule G; Boakye-Yiadom E; Agbavor B; Sarpong F; Ahor H; Adu E; Danso KG; Abass MK; Asiedu K; Wansbrough-Jones M; Phillips RO
J Med Case Rep; 2019 Jul; 13(1):218. PubMed ID: 31315637
[TBL] [Abstract][Full Text] [Related]
10. Management of Mycobacterium ulcerans infection in a pregnant woman in Benin using rifampicin and clarithromycin.
Dossou AD; Sopoh GE; Johnson CR; Barogui YT; Affolabi D; Anagonou SY; Zohoun T; Portaels F; Asiedu K
Med J Aust; 2008 Nov; 189(9):532-3. PubMed ID: 18976206
[No Abstract] [Full Text] [Related]
11. Drugs for treating Buruli ulcer (Mycobacterium ulcerans disease).
Yotsu RR; Richardson M; Ishii N
Cochrane Database Syst Rev; 2018 Aug; 8(8):CD012118. PubMed ID: 30136733
[TBL] [Abstract][Full Text] [Related]
12. Compliance with antimicrobial therapy for buruli ulcer.
Klis S; Kingma R; Tuah W; Stienstra Y; van der Werf TS
Antimicrob Agents Chemother; 2014 Oct; 58(10):6340. PubMed ID: 25225342
[No Abstract] [Full Text] [Related]
13. Reply to "compliance with antimicrobial therapy for buruli ulcer".
Phillips RO; Sarfo FS; Abass MK; Frimpong M; Ampadu E; Forson M; Amoako YA; Thompson W; Asiedu K; Wansbrough-Jones M
Antimicrob Agents Chemother; 2014 Oct; 58(10):6341. PubMed ID: 25225343
[No Abstract] [Full Text] [Related]
14. Chemotherapy-associated changes of histopathological features of Mycobacterium ulcerans lesions in a Buruli ulcer mouse model.
Ruf MT; Schütte D; Chauffour A; Jarlier V; Ji B; Pluschke G
Antimicrob Agents Chemother; 2012 Feb; 56(2):687-96. PubMed ID: 22143518
[TBL] [Abstract][Full Text] [Related]
15. Triple oral beta-lactam containing therapy for Buruli ulcer treatment shortening.
Arenaz-Callao MP; González Del Río R; Lucía Quintana A; Thompson CJ; Mendoza-Losana A; Ramón-García S
PLoS Negl Trop Dis; 2019 Jan; 13(1):e0007126. PubMed ID: 30689630
[TBL] [Abstract][Full Text] [Related]
16. Increasing Experience with Primary Oral Medical Therapy for Mycobacterium ulcerans Disease in an Australian Cohort.
Friedman ND; Athan E; Walton AL; O'Brien DP
Antimicrob Agents Chemother; 2016 May; 60(5):2692-5. PubMed ID: 26883709
[TBL] [Abstract][Full Text] [Related]
17. Antimicrobial treatment for early, limited Mycobacterium ulcerans infection: a randomised controlled trial.
Nienhuis WA; Stienstra Y; Thompson WA; Awuah PC; Abass KM; Tuah W; Awua-Boateng NY; Ampadu EO; Siegmund V; Schouten JP; Adjei O; Bretzel G; van der Werf TS
Lancet; 2010 Feb; 375(9715):664-72. PubMed ID: 20137805
[TBL] [Abstract][Full Text] [Related]
18. Targeting the Mycobacterium ulcerans cytochrome bc
Scherr N; Bieri R; Thomas SS; Chauffour A; Kalia NP; Schneide P; Ruf MT; Lamelas A; Manimekalai MSS; Grüber G; Ishii N; Suzuki K; Tanner M; Moraski GC; Miller MJ; Witschel M; Jarlier V; Pluschke G; Pethe K
Nat Commun; 2018 Dec; 9(1):5370. PubMed ID: 30560872
[TBL] [Abstract][Full Text] [Related]
19.
Kwofie SK; Dankwa B; Odame EA; Agamah FE; Doe LPA; Teye J; Agyapong O; Miller WA; Mosi L; Wilson MD
Molecules; 2018 Jun; 23(7):. PubMed ID: 29954088
[TBL] [Abstract][Full Text] [Related]
20. Microbiology of secondary infections in Buruli ulcer lesions; implications for therapeutic interventions.
Gyamfi E; Narh CA; Quaye C; Abbass A; Dzudzor B; Mosi L
BMC Microbiol; 2021 Jan; 21(1):4. PubMed ID: 33402095
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
